Pedro Giavina-Bianchi, M., Eric Cua, M., Karine Risso, M., Véronique Mondain, M., Anaïs Vissian, M., Cécile Joie, M., . . . Jorge Kalil, M. (2023). ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: MiR-AGE, a randomized, double-blind placebo-controlled trial. Elsevier.
Chicago Style (17th ed.) CitationPedro Giavina-Bianchi, MD, et al. ABX464 (obefazimod) for Patients with COVID-19 at Risk for Severe Disease: MiR-AGE, a Randomized, Double-blind Placebo-controlled Trial. Elsevier, 2023.
MLA (9th ed.) CitationPedro Giavina-Bianchi, MD, et al. ABX464 (obefazimod) for Patients with COVID-19 at Risk for Severe Disease: MiR-AGE, a Randomized, Double-blind Placebo-controlled Trial. Elsevier, 2023.
Warning: These citations may not always be 100% accurate.